222 



nies had added or spiked their tobacco products with nicotine addi- 

 tives. I told the agents in very clear terms that I had not heard 

 or seen any such thing in all of my years at Brown & Williamson. 



By the way, this gentleman was an engineer with the company 

 and he served in that capacity in every manufacturing plant oper- 

 ated by Brown & Williamson in the continental United States he 

 says here in his affidavit. 



I told the agents in very clear terms that I had not heard or seen 

 any such thing in all of my years at Brown & Williamson. I also 

 told him that I designed much of the equipment and was familiar 

 with the rest of the equipment which was used in making the ciga- 

 rettes and I would know if any spiking or the like was being done. 

 The agent, Jim Hunter, told me in response that, yes, we know 

 that now. Yes, we know that now. 



I'm wondering whether this documentation or any memorandums 

 of these conversations are going to be some of the stuff that is 

 going to be furnished to the committee within a couple of weeks be- 

 cause we asked for any memorandums or whatnot, and I would 

 imagine something like this is on record. 



This seemed to end the conversation about the nicotine additive 

 issue. I asked Jim Hunter how he found — are we getting 5 minutes 

 or 10 minutes, Mr. Chairman. 



Mr. Waxman. Ten minutes. 



Mr. BiLlRAKlS. Ten minutes has gone by? 



Mr. Waxman. It has. 



Mr. BiLlRAKlS. Well, may I just ask one further question of unan- 

 imous consent. 



Mr. Waxman. Go ahead. 



Mr. BILIRAKIS. Mr. President, I'm not sure whether we are going 

 to have a second round. We are never sure we are going to be here 

 for the second round. I guess the chairman is always sure, but the 

 rest of us aren't. There is a vote on the Floor. In case for some rea- 

 son I'm not here to go further into this, I wonder if you would fur- 

 nish information for the record regarding some of these things that 

 have taken place regarding Brown & Williamson employees. 



I used the term harassment. I'm not sure that it applied to the 

 one that I talked about, but there are affidavits here from Susan 

 Beaseley and some others that would indicate that was the case. 



Mr. Sandefur. Congressman, I would be more than happy to 

 supply that. As a matter of fact, there is a young lady here today 

 in this conference room who was the subject of this investigation 

 and I asked her to come before this committee if you all are inter- 

 ested in having her testify as to what happened. 



I find it highly unusual that a Federal agency would go about an 

 investigation in this manner, particularly given the fact that my 

 company has stated time and time again to this subcommittee and 

 to the FDA that we would be more than happy to cooperate and 

 answer any questions they might have. But they chose not to do 

 it that way. 



Mr. BiLlRAKis. And I know the committee chairman and most 

 members of this committee, ordinarily, when they are aware that 

 something like this might be happening, are very concerned and 

 certainly sometimes hold hearings right on point, right on that par- 

 ticular issue. So I would expect that the committee and the chair- 



